ProTCE-PSMA
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
ProTCE-PSMA, a novel therapeutic PSMA/CD3 prodrug for prostate cancer
(AACR 2026)
- "Abstract is embargoed at this time."
Late-breaking abstract • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
1 to 1
Of
1
Go to page
1